Last reviewed · How we verify

recomon (Epoetin Beta) — Competitive Intelligence Brief

recomon (Epoetin Beta) (recomon (Epoetin Beta)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoiesis-stimulating agent (ESA). Area: Hematology.

marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR) Hematology Small molecule Live · refreshed every 30 min

Target snapshot

recomon (Epoetin Beta) (recomon (Epoetin Beta)) — JW Pharmaceutical. Recomon is a recombinant erythropoietin (EPO) that stimulates erythropoiesis by binding to the erythropoietin receptor on bone marrow progenitor cells to increase red blood cell production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
recomon (Epoetin Beta) TARGET recomon (Epoetin Beta) JW Pharmaceutical marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
Epogen Epoetin Alfa-Epbx Amgen marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor 1989-01-01
ARM B: IV iron + epoietin zeta sequence ARM B: IV iron + epoietin zeta sequence Centre Francois Baclesse marketed Iron supplement + Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR); iron as cofactor for hemoglobin synthesis
Epoetin β (450 UI/kg/week) Epoetin β (450 UI/kg/week) Germans Trias i Pujol Hospital marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
epoetin epoetin Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor
Erythropoietin carried on chitosan carrier Erythropoietin carried on chitosan carrier Ain Shams University marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)
continuation (darbepoetinum) continuation (darbepoetinum) Anemia Working Group Romania marketed Erythropoiesis-stimulating agent (ESA) Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoiesis-stimulating agent (ESA) class)

  1. Amgen · 4 drugs in this class
  2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 3 drugs in this class
  3. Hospital de Clinicas de Porto Alegre · 2 drugs in this class
  4. Pfizer · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Chong Kun Dang Pharmaceutical · 2 drugs in this class
  7. Barts & The London NHS Trust · 1 drug in this class
  8. Australian and New Zealand Intensive Care Research Centre · 1 drug in this class
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  10. Biocad · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). recomon (Epoetin Beta) — Competitive Intelligence Brief. https://druglandscape.com/ci/recomon-epoetin-beta. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: